MAHWAH, N.J., Nov. 15, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals, a global pharmaceutical company, today announced
"Nearly 50% of people with SAR rely on multiple therapies to treat their symptoms,1 and this poly treatment approach may be ineffective or suboptimal for many of these patients,"2 said Mahboob Rahman, President and Chief Medical Officer at Glenmark Pharmaceuticals. "We look forward to sharing efficacy data, as well as long-term safety data on Ryaltris, at ACAAI 2018."
The scheduled times (noted in Pacific time) of the presentations at the Washington State Convention Center are as follows:
About Seasonal Allergic RhinitisAccording to the most recent CDC data, over 17 million adults in the United States are affected by seasonal allergic rhinitis every year.3 It is the primary diagnosis in over 11 million doctor's visits annually and is estimated to affect more than seven percent of adults aged 18 and over in the United States.3,4
About Glenmark's Respiratory PipelineGlenmark's respiratory pipeline is specifically aimed at addressing the global public health burden of allergic rhinitis, asthma and chronic obstructive pulmonary disease (COPD), and includes investigational treatments across the disease spectrum. This includes Ryaltris (GSP 301 Nasal Spray), an investigational combination antihistamine plus steroid nasal spray for the treatment of seasonal allergic rhinitis. It also includes GBR 310 (omalizumab), a proposed biosimilar candidate intended for the treatment of allergic asthma and chronic idiopathic urticaria; and GRC 39815, which is being investigated pre-clinically for the treatment of COPD and other respiratory diseases.
About Glenmark Pharmaceuticals Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology. Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years. For more information, visit https://www.glenmarkpharma-us.com/.
View original content:http://www.prnewswire.com/news-releases/glenmark-pharmaceuticals-announces-new-data-presentations-on-ryaltris-at-the-acaai-annual-scientific-meeting-2018-300750807.html
SOURCE Glenmark Pharmaceuticals
Subscribe to our Free Newsletters!